Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Sylvan SE, Asklid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, Kimby E, Norin S, Andersson PO, Karlsson C, Karlsson K, Lauri B, Mattsson M, Sandstedt AB, Strandberg M, Österborg A, Hansson L. Sylvan SE, et al. Among authors: johansson h. Haematologica. 2019 Apr;104(4):797-804. doi: 10.3324/haematol.2018.200204. Epub 2018 Nov 22. Haematologica. 2019. PMID: 30467205 Free PMC article. Clinical Trial.
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Mulligan SP, Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerström J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundström G, Johansson H, Brandberg Y, Liliemark J, Juliusson G; Scandinavian and Australasian Leukaemia Lymphoma Groups (Allg). Mulligan SP, et al. Among authors: johansson h. Leuk Lymphoma. 2014 Dec;55(12):2769-77. doi: 10.3109/10428194.2014.893306. Epub 2014 Apr 16. Leuk Lymphoma. 2014. PMID: 24524339 Clinical Trial.
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy.
Asklid A, Eketorp Sylvan S, Mattsson A, Winqvist M, Johansson H, Österborg A, Hansson L. Asklid A, et al. Among authors: johansson h. Leuk Lymphoma. 2020 Sep;61(9):2136-2144. doi: 10.1080/10428194.2020.1765233. Epub 2020 May 25. Leuk Lymphoma. 2020. PMID: 32449636
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Mattsson A, Sylvan SE, Asklid A, Wiggh J, Winqvist M, Lundin J, Mansouri L, Rosenquist R, Johansson H, Österborg A, Hansson L. Mattsson A, et al. Among authors: johansson h. Br J Haematol. 2020 Nov;191(3):426-432. doi: 10.1111/bjh.17032. Epub 2020 Aug 10. Br J Haematol. 2020. PMID: 32779190 Free PMC article.
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Blixt L, Bogdanovic G, Buggert M, Gao Y, Hober S, Healy K, Johansson H, Kjellander C, Mravinacova S, Muschiol S, Nilsson P, Palma M, Pin E, Smith CIE, Stromberg O, Sällberg Chen M, Zain R, Hansson L, Österborg A. Blixt L, et al. Among authors: johansson h. Leukemia. 2022 Feb;36(2):476-481. doi: 10.1038/s41375-021-01424-w. Epub 2021 Sep 25. Leukemia. 2022. PMID: 34564699 Free PMC article.
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
Mattsson A, Sylvan SE, Axelsson P, Ellin F, Kjellander C, Larsson K, Lauri B, Lewerin C, Scharenberg C, Tätting L, Johansson H, Österborg A, Hansson L. Mattsson A, et al. Among authors: johansson h. Eur J Haematol. 2023 Nov;111(5):715-721. doi: 10.1111/ejh.14065. Epub 2023 Jul 27. Eur J Haematol. 2023. PMID: 37501508 Free article.
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region.
Andersson ML, Johansson H, Österborg A, Månsson-Broberg A, Hansson L, Palma M. Andersson ML, et al. Among authors: johansson h. Eur J Haematol. 2023 Nov;111(5):748-756. doi: 10.1111/ejh.14072. Epub 2023 Aug 10. Eur J Haematol. 2023. PMID: 37565648
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
Brandberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J; Nordic Melanoma Cooperative Group. Brandberg Y, et al. Among authors: johansson h. Acta Oncol. 2013 Aug;52(6):1086-93. doi: 10.3109/0284186X.2013.789140. Epub 2013 Apr 28. Acta Oncol. 2013. PMID: 23621752 Clinical Trial.
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C, Hertzman Johansson C, Lindén D, Johansson H, Frostvik Stolt M, Walker C, Snowden H, Newton-Bishop J, Hansson J, Egyházi Brage S. Tuominen R, et al. Among authors: johansson h. Int J Cancer. 2015 Jun 15;136(12):2844-53. doi: 10.1002/ijc.29332. Epub 2014 Nov 24. Int J Cancer. 2015. PMID: 25400033
1,468 results